Silence Therapeutics Posts First Human Data For Cardiovascular Candidate
Silence Therapeutics plc (NASDAQ: SLN) showed that its RNAi technology could
Silence Therapeutics Announces Topline Data In SLN360 Phase 1 Single-Ascending Dose Study In Healthy Adults With High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”)
The Daily Biotech Pulse: Moderna’s Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
